Biogen (NASDAQ: BIIB) made headlines on the stock market recently after announcing its quarterly earnings, which surpassed analysts’ expectations and led to a notable increase in its stock price. By the end of the trading day, shares of the prominent biotech company had risen by 6%.
In the first quarter of 2026, Biogen reported total revenue of $2.48 billion, marking a 2% increase compared to the same quarter last year. This figure exceeded the consensus estimate of $2.25 billion, indicating strong performance despite the company’s struggles in other areas. The company’s attributable net income, calculated not under generally accepted accounting principles (GAAP), improved significantly as well, climbing 19% to over $529 million, or $3.57 per share—well above analysts’ expectations of $2.95.
A major driver of this revenue growth was Biogen’s “growth products” portfolio, particularly the sales of Leqembi, which aims to treat early Alzheimer’s disease and saw a remarkable increase of 74% to $168 million. Additionally, another product, Skyclarys, noted robust growth as it remains the only FDA-approved medication for Friedreich’s ataxia, contributing to the company’s pipeline diversification.
However, not all news from Biogen was positive. The company announced a cut to its full-year profitability guidance, now estimating adjusted net income between $14.25 and $15.25 per share, a reduction of $1 on both ends from the previous forecast of $15.25 to $16.25. This adjustment is attributed to anticipated charges related to acquired in-process research and development. Furthermore, Biogen projects revenue to decline at a mid-single-digit percentage rate compared to 2025, although these projections do not factor in the upcoming acquisition of Apellis Pharmaceuticals, valued at $5.6 billion, which is expected to finalize soon.
As Biogen continues its strategic shift from a focus on multiple sclerosis treatments to other high-potential therapies, many analysts express optimism about the company’s long-term growth prospects. With the current trajectory, some industry experts believe that Biogen’s approach will yield continual positive results, leading them to endorse buying Biogen stock.
However, potential investors are advised to consider other opportunities as well. A report from the Motley Fool Stock Advisor lists ten stocks considered more appealing for investment at this time, none of which includes Biogen. The historical performance of these recommended stocks has significantly outperformed the market, implying that investors should weigh Biogen’s prospects against those of other potentially lucrative investments.
Overall, while Biogen’s recent earnings report has garnered positive attention, it remains crucial for investors to conduct thorough research and consider broader market trends before making investment decisions.
